企業概要
Generation Bio Co. is a biotechnology enterprise focused on discovering, developing, and commercializing redosable therapeutics designed to reprogram T cells within the body to reduce or eliminate the production and persistence of autoreactive T cells. The company operates within the Healthcare sector, specifically in the Biotechnology industry, an area characterized by high research intensity and the development of innovative medical treatments for various diseases. As of the latest available data, the entity maintains a market capitalization of $35.98M, reports an annual revenue of $15.27M, and employs 115 individuals. These financial figures indicate that Generation Bio Co. is a mid-to-small-sized biotechnology firm with a relatively modest revenue base compared to large-cap pharmaceutical peers, reflecting its stage in the development lifecycle where significant resources are still required to advance its pipeline from discovery to commercialization.
財務健全性
The company reported a revenue of $15.27M over the trailing twelve months, while simultaneously posting a net income loss of $-62,627,000 and an EBITDA of $-76,380,000, highlighting a substantial gap between top-line generation and profitability. This wide disparity between revenue and net income reveals a cost structure dominated by heavy research and development expenses or general and administrative costs that significantly outpace current sales, which is typical for early-stage biotechnology companies. Free cash flow stands at $-40,196,752, indicating that the company is burning through its liquidity to fund operations and R&D, thereby limiting its immediate financial flexibility without external capital injections. The gross margin is listed at -212.2%, the operating margin at -2020.0%, and the profit margin at 0.0%, all of which reflect the intense cost-to-revenue pressure and the lack of scalable profitability in the current reporting period. Regarding liquidity, the firm holds $89.62M in cash against $26.10M in debt, resulting in a debt-to-equity ratio of 51.61, which suggests a leveraged balance sheet structure where debt obligations are substantial relative to equity. Despite the leverage, the current ratio of 4.44 indicates strong short-term liquidity, as the company possesses more than four times the current assets required to cover its current liabilities. Return on equity is -80.8% and return on assets is -27.4%, metrics that demonstrate that management's effectiveness in generating profit from shareholder capital and total assets is currently negative due to the company's operational losses.
バリュエーション評価
The trailing twelve-month P/E ratio is N/A, while the forward P/E is -3.99, implying that the market is pricing in a period of continued negative earnings before moving toward profitability, rather than valuing current earnings power. The price-to-book ratio stands at 0.71, indicating that the market values the company at a discount relative to its book value, a common characteristic for distressed or pre-profit biotechnology firms where intangible assets may not be fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 2.36 and an EV/EBITDA of 0.36 suggest that investors are paying a premium relative to sales but a negligible multiple relative to earnings, reflecting the high risk associated with the company's lack of positive EBITDA. The stock has traded between a 52-week high of $7.60 and a 52-week low of $3.00, and depending on the current trading price, the security fluctuates within this established volatility range which is typical for small-cap biotech stocks. The beta of 2.01 signifies that the stock price is highly volatile and tends to move with more than double the magnitude of the broader market index, exposing investors to significant price swings during periods of market turbulence.
Growth & Income
Revenue growth year-over-year is -78.9%, while earnings growth is N/A due to the lack of positive net income, indicating a contraction in sales rather than the expansion often required in the biotechnology sector. Since the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, any earnings generated in the future would likely be reinvested into growth initiatives rather than distributed to shareholders. The absence of a dividend policy is consistent with the company's lifecycle stage, where capital retention is prioritized to sustain R&D programs and operational burn rates. Overall, the growth and income profile is defined by negative revenue expansion and a complete lack of current income distribution, presenting a high-risk, capital-depleting scenario until the company can achieve commercial milestones.